帕博西尼-话题@MedSci

#帕博西尼#

11篇内容 | 1838人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2257936, encodeId=57e6225e93672, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=b4975869e17' target=_blank style='color:#2F92EE;'>#新辅助化疗#</a> <a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Ann. Oncol：帕博西尼在早期高风险HR阳性、HER2阴性乳腺癌中的应用（Penelope-B试验）, objectType=article, longId=869123, objectId=274d869123b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241104/1730709928220_8538692.png, objectUrl=/article/show_article.do?id=274d869123b0, replyNumber=0, likeNumber=11, createdTime=2025-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=274d869123b0, moduleTitle=Ann. Oncol：帕博西尼在早期高风险HR阳性、HER2阴性乳腺癌中的应用（Penelope-B试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274d869123b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2253056, encodeId=aeca22530561c, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=ade83034098' target=_blank style='color:#2F92EE;'>#内分泌治疗#</a> <a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Lancet Oncol：帕博西尼联合内分泌治疗与卡培他滨在激素受体阳性、HER2阴性转移性乳腺癌绝经前女性中的比较：Young-PEARL研究的总体生存分析, objectType=article, longId=864253, objectId=2b79864253f1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240925/1727257009596_8538692.png, objectUrl=/article/show_article.do?id=2b79864253f1, replyNumber=0, likeNumber=21, createdTime=2025-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=四川省, moduleDTOList=[ModuleDTO(moduleId=2b79864253f1, moduleTitle=Lancet Oncol：帕博西尼联合内分泌治疗与卡培他滨在激素受体阳性、HER2阴性转移性乳腺癌绝经前女性中的比较：Young-PEARL研究的总体生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b79864253f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213638, encodeId=f61e2213638c1, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a> <a href='/topic/show?id=433810968558' target=_blank style='color:#2F92EE;'>#EGFR基因突变#</a>, objectTitle=靶向药联起来用？只要有基因突变线索奥希替尼和帕博西尼联用也有效！, objectType=article, longId=832181, objectId=ea2e8321815e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240706/1720276834182_5579292.jpg, objectUrl=/article/show_article.do?id=ea2e8321815e, replyNumber=0, likeNumber=115, createdTime=2024-07-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ea2e8321815e, moduleTitle=靶向药联起来用？只要有基因突变线索奥希替尼和帕博西尼联用也有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea2e8321815e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197021, encodeId=5160219e021ab, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a> <a href='/topic/show?id=fc9744059a' target=_blank style='color:#2F92EE;'>#CDK4/6抑制剂#</a> <a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=JCO | PACE试验：氟维司群+帕博西尼+阿维鲁单抗（F+P+A）方案在CDK4/6抑制剂进展后激素受体阳性/HER2阴性转移性乳腺癌患者中具有较好的疗效和安全性, objectType=article, longId=820328, objectId=3356820328d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240404/1712236824458_6145188.jpg, objectUrl=/article/show_article.do?id=3356820328d0, replyNumber=0, likeNumber=125, createdTime=2024-04-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3356820328d0, moduleTitle=JCO | PACE试验：氟维司群+帕博西尼+阿维鲁单抗（F+P+A）方案在CDK4/6抑制剂进展后激素受体阳性/HER2阴性转移性乳腺癌患者中具有较好的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3356820328d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191240, encodeId=2bb8219124054, content=<a href='/topic/show?id=3c1ee4340c9' target=_blank style='color:#2F92EE;'>#神经母细胞瘤#</a> <a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Dev Cell：帕博西尼显著提高神经母细胞瘤分化，有望改善现有疗法, objectType=article, longId=813023, objectId=3c618130238b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=3c618130238b, replyNumber=0, likeNumber=87, createdTime=2024-03-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3c618130238b, moduleTitle=Dev Cell：帕博西尼显著提高神经母细胞瘤分化，有望改善现有疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c618130238b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1492026, encodeId=fa6d1492026e8, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法, objectType=article, longId=730360, objectId=9feee303606b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9feee303606b, replyNumber=0, likeNumber=112, createdTime=2022-06-25, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9feee303606b, moduleTitle=Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9feee303606b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492025, encodeId=bc87149202501, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, objectType=article, longId=301809, objectId=25d630180953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25d630180953, replyNumber=0, likeNumber=181, createdTime=2022-03-29, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25d630180953, moduleTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25d630180953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492024, encodeId=93691492024b9, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群, objectType=article, longId=218872, objectId=63df2188e27d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df2188e27d, replyNumber=0, likeNumber=131, createdTime=2021-10-20, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df2188e27d, moduleTitle=JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df2188e27d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492023, encodeId=d4f0149202382, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果, objectType=article, longId=218363, objectId=b482218363b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b482218363b0, replyNumber=0, likeNumber=119, createdTime=2021-10-12, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b482218363b0, moduleTitle=Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b482218363b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492022, encodeId=3ebd1492022a6, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, objectType=article, longId=214063, objectId=7ac421406392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac421406392, replyNumber=0, likeNumber=94, createdTime=2021-07-13, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac421406392, moduleTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac421406392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492021, encodeId=2bd41492021b6, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌, objectType=article, longId=205891, objectId=075d205891cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d205891cb, replyNumber=0, likeNumber=135, createdTime=2021-01-21, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d205891cb, moduleTitle=Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d205891cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492020, encodeId=ccfa149202056, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Lancet oncol：内分泌疗法加用帕博西尼是否可进一步改善早期乳腺癌患者预后？, objectType=article, longId=205838, objectId=7aaf20583880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aaf20583880, replyNumber=0, likeNumber=160, createdTime=2021-01-20, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aaf20583880, moduleTitle=Lancet oncol：内分泌疗法加用帕博西尼是否可进一步改善早期乳腺癌患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aaf20583880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492019, encodeId=47b1149201991, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, objectType=article, longId=182128, objectId=7074182128d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7074182128d0, replyNumber=0, likeNumber=105, createdTime=2019-10-31, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7074182128d0, moduleTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7074182128d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, objectType=article, longId=159650, objectId=141815965033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141815965033, replyNumber=0, likeNumber=103, createdTime=2019-02-10, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141815965033, moduleTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141815965033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492017, encodeId=e378149201e89, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究, objectType=article, longId=151455, objectId=558a15145559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558a15145559, replyNumber=0, likeNumber=108, createdTime=2018-10-22, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558a15145559, moduleTitle=Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=558a15145559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1492016, encodeId=5c50149201659, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, objectTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, objectType=article, longId=126038, objectId=58561260389d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58561260389d, replyNumber=0, likeNumber=104, createdTime=2018-01-11, rootId=0, userName=nymo, userId=9dde8911885, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58561260389d, moduleTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58561260389d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

帕博西尼

2020-05-29

梅斯管理员

#乳腺癌# #新辅助化疗# #帕博西尼#

Ann. Oncol：帕博西尼在早期高风险HR阳性、HER2阴性乳腺癌中的应用（Penelope-B试验）

2025-03-27发表于陕西省

梅斯管理员

#乳腺癌# #内分泌治疗# #帕博西尼#

Lancet Oncol：帕博西尼联合内分泌治疗与卡培他滨在激素受体阳性、HER2阴性转移性乳腺癌绝经前女性中的比较：Young-PEARL研究的总体生存分析

2025-02-22发表于四川省

梅斯管理员

#肺癌# #奥希替尼# #帕博西尼# #EGFR基因突变#

靶向药联起来用？只要有基因突变线索奥希替尼和帕博西尼联用也有效！

2024-07-06发表于上海

梅斯管理员

#乳腺癌# #氟维司群# #CDK4/6抑制剂# #帕博西尼#

JCO | PACE试验：氟维司群+帕博西尼+阿维鲁单抗（F+P+A）方案在CDK4/6抑制剂进展后激素受体阳性/HER2阴性转移性乳腺癌患者中具有较好的疗效和安全性

2024-04-05发表于上海

梅斯管理员

#神经母细胞瘤# #帕博西尼#

Dev Cell：帕博西尼显著提高神经母细胞瘤分化，有望改善现有疗法

2024-03-05发表于上海

nymo

#帕博西尼#

Clin Cancer Res：帕博西尼+氟维司群联合方案或可成为晚期乳腺癌的标准疗法

2022-06-25

nymo

#帕博西尼#

Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗

2022-03-29

nymo

#帕博西尼#

JAMA Oncol：对于激素受体阳性乳腺癌，帕博西尼 ➕来曲唑优于帕博西尼 ➕氟维司群

2021-10-20

nymo

#帕博西尼#

Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果

2021-10-12

nymo

#帕博西尼#

Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性

2021-07-13

nymo

#帕博西尼#

Ann Oncol：3期| 帕博西尼+内分泌治疗 vs 化疗用于ER+HER2-芳香化酶抑制剂耐药的转移性乳腺癌

2021-01-21

nymo

#帕博西尼#

Lancet oncol：内分泌疗法加用帕博西尼是否可进一步改善早期乳腺癌患者预后？

2021-01-20

nymo

#帕博西尼#

Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌

2019-10-31

nymo

#帕博西尼#

Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

2019-02-10

nymo

#帕博西尼#

Brit J Cancer：转移性尿路上皮癌患者首次化疗失败后，帕博西尼第二阶段临床试验研究

2018-10-22

nymo

#帕博西尼#

Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。

2018-01-11